XOMA - XOMA Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
14.65
-0.35 (-2.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.00
Open14.99
Bid0.00 x 800
Ask16.78 x 1000
Day's Range14.23 - 15.30
52 Week Range13.60 - 37.25
Volume72,166
Avg. Volume92,198
Market Cap122.872M
Beta (3Y Monthly)4.12
PE Ratio (TTM)7.78
EPS (TTM)1.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.50
Trade prices are not sourced from all markets
  • GlobeNewswire26 days ago

    XOMA to Present at the Cantor Fitzgerald Healthcare Conference 2018 and the 2018 BIO Investor Forum

    XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  For more information, visit www.xoma.com.

  • The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Could Be Important
    Simply Wall St.29 days ago

    The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Could Be Important

    A look at the shareholders of XOMA Corporation (NASDAQ:XOMA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insidersRead More...

  • GlobeNewswirelast month

    XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte

    EMERYVILLE, Calif., Sept. 21, 2018-- XOMA Corporation, announced today that for $15.0 million, it has acquired from Agenus a partial interest position in the rights to potential milestone and royalty payments ...

  • GlobeNewswire2 months ago

    XOMA to Present at the H. C. Wainwright 20th Annual Global Investment Conference

    XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, announced today its Chief Executive Officer, Jim Neal, will present at the H. C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018, at 11:40-12:05PM ET in New York, New York. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit www.xoma.com.

  • GlobeNewswire2 months ago

    XOMA to Present at the 2018 Wedbush PacGrow Healthcare Conference and the 2018 Southern California Investor Conference

    XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit www.xoma.com.

  • Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Xoma: 2Q Earnings Snapshot

    The Emeryville, California-based company said it had a loss of 23 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire3 months ago

    XOMA Reports Second Quarter 2018 Financial Results

    EMERYVILLE, Calif., Aug. 07, 2018-- XOMA Corporation, a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced its second quarter 2018 financial results.. “We continue ...

  • GlobeNewswire3 months ago

    Detailed Research: Economic Perspectives on Alleghany, Enable Midstream Partners, LP, XOMA, MCBC, Unifi, and Tyler Technologies — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Aug. 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alleghany ...

  • Associated Press5 months ago

    Xoma: 1Q Earnings Snapshot

    The Berkeley, California-based company said it had a loss of 46 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Associated Press8 months ago

    Xoma reports 4Q loss

    The Berkeley, California-based company said it had a loss of 16 cents per share. The drug developer posted revenue of $5.4 million in the period. For the year, the company reported net income of $14.6 ...

  • AbbVie Presents New Data on Upadacitinib for Crohn's Disease
    Zacks8 months ago

    AbbVie Presents New Data on Upadacitinib for Crohn's Disease

    AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

  • FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
    Zacks8 months ago

    FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review

    FDA accepts Agios' NDA for its pipeline candidate ivosidenib (AG-120) and sets an action date of Aug 21, 2018.

  • AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
    Zacks8 months ago

    AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

    AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

  • Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
    Zacks8 months ago

    Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

    Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

  • Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
    Zacks8 months ago

    Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down

    Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.